menu

Are You Ready for Biosimilars? What the Oncology Team Should Know

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Menopause

Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

Program Information

Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know
RestartResume

Explore the difference between generics and biosimilars along with the biosimilar development pathway in the first episode of this two-part video.

  • Sponsored by

  • Overview

    What’s the difference between a generic drug and biosimilar? How does the FDA define biosimilarity? And how are biosimilars developed? Get answers to these and other questions with Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC, in the first episode of this two-part video.

                                                                                ©2020 Amgen Inc. All rights reserved. USA-CBU-80726 10/20

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/1/20